Questions: Curious who might know the answer to any of these questions?
1.) Is the STXS ICE catheter exclusive to their system? Very Important. 2.) What is the total mrkt for ICE? Do you know who plays is this sandbox? BSX, STJ, JNJ. Who are the most likely takeout candidates? MDT? 3.) Do the EP's really like a magnetic nav system, radiation reduction? 4.) What is the install base here in the US with STXS? 4.) At current MRKT CAP/ $60M, would it be wise to wipe out StXS for $80-100M? I work with EP's everyday and will get answers to some of these questions but I do believe STXS will survive and see a great turn around although I expect a significant pullback of PPS. IMO
I expect this to be at $3-$4 range until they prove that they can be profitable. You have to remember that all of their products have been in in motion since 2011 in Europe and Asia. They've been losing money over and over to the point that they will be delisted since they can't comply with Nasdaq rules, to maintain 50 million in assets and revenues. That's quite pathetic. Their revenues are only 11 million yet the market is valuing the company at 75 million right now at $7 a share. That's horrible.
Their equipment costs a lot of money and they require experts to operate it. Physicans don't want to use it since there's a huge learning curve and there are other, replaceable products out there. ISRG runs the robotic division. This is why they're losing money all over the world. FDA approval in USA doesnt mean much. Lots of competition and costs are too high. Obamacare won't cover that, hell I know for a fact they won't. I work in healthcare sector and we're trying to cut costs, not increase them. So, this is going to pink sheets in September. They don't make money. That's why CEO and CFO quit!
Kiksbutt, you're certainly active on both the STXS message board and market pulse. I take it that you're short. You must have been on pins and needles and sweating your short position all weekend. Good luck to your short position on Monday.